CStone Pharmaceuticals-B (02616) rose more than 6% again, bringing its cumulative increase for the month to over 25%. As of the time of writing, the stock was up 5.03%, trading at HK$6.68 with a turnover of HK$102 million. On February 23, the company announced that its PD-L1 antibody, sugemalimab, has received formal approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a new indication in Stage III non-small cell lung cancer (NSCLC). This approval marks another key breakthrough in core European markets, following the European Commission's authorization in July 2024. In addition, CStone's core asset CS2009 recently obtained FDA approval for its Investigational New Drug (IND) application for a Phase II clinical trial targeting advanced solid tumors. The approval of the IND for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, signifies important progress in the global development of this innovative immunotherapy.